Purchase Order 75N95023P00560
Award Date 9/21/23
Potential Completion Date 12/20/23
Potential Value $24K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27707, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a $240,000.00 firm fixed-price purchase order to Chemogenics Biopharma, LLC, a for-profit limited liability company, for custom synthesis and bioanalytical services to support NCATS' internal projects focused on developing small molecule inhibitors of physiological small molecule methyltransferases. The 12-month contract is not set aside and is awarded under FAR Part 13 simplified...
- This is a $24,900.00 firm fixed price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Chemogenics Biopharma, LLC, a for-profit limited liability company and sole proprietorship, on July 23, 2019. The contract has a completion date of September 30, 2019 and does not have a set-aside designation. Chemogenics Biopharma, LLC is a leading company in preclinical drug discovery and has been awarded several...
- The National Institute on Drug Abuse awarded a $101,000 firm fixed-price purchase order to Chemogenics Biopharma, LLC on September 16, 2025, for synthesis and bioanalytical analysis services supporting the National Center for Advancing Translational Sciences (NCATS) Early Translational Branch Chemistry Program. The contract, which extends through July 15, 2026, is performable in Durham, North Carolina. This procurement does not utilize a small business set-aside designation. The work involves...
- This is a $249,500 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Chemogenics Biopharma, LLC, a small business. The contract is for synthesis and bioanalytical analysis support services related to the therapeutic areas of the microbiome, neurodegeneration, and addiction. The services will augment existing medicinal chemistry campaigns within the National Center for Advancing Translational...
- The National Center for Advancing Translational Sciences awarded a firm fixed-price purchase order to Pharmaron, Inc. valued at $50,300 on September 14, 2026, for mouse pharmacokinetic/pharmacodynamic study services on NNMT inhibitors. Work is performed in Rockville, Maryland. The contract requires single-dose oral and intravenous studies in mice across ten NNMT inhibitor test articles, with a sample size of three mice per time point, plasma concentration data collection, and pharmacokinetic...
- This contract award to Gempharmatech LLC, a foreign-owned biotechnology company in San Diego, California, is for a $58,936 fixed-price purchase order to evaluate the safety of the compound YC1 in mice with humanized SULT1A1 proteins versus standard mouse SULT1A1 proteins. The contract was awarded by the National Center for Advancing Translational Sciences (NCATS), which operates under the National Institutes of Health within the Department of Health and Human Services. The objective is to...
- This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency, to Chemgenes Corporation for $3,499.01. The contract has no set-aside designation and the ultimate completion date is March 1, 2016. Chemgenes Corporation is a minority-owned, for-profit, and woman-owned business located in Wilmington, Massachusetts. The place of performance is Research Triangle Park, North Carolina. This contract award does not appear...
- Medchemexpress LLC has been awarded a firm fixed price purchase order valued at $24,700 by the National Institutes of Health's National Center for Advancing Translational Sciences to provide 29 compounds in support of the agency's Tox21 research project examining the NS3-NS2B complex. As part of its mission to translate scientific discoveries into clinical applications, NCATS utilizes screening programs like Tox21 to evaluate the effects of environmental chemicals on biological pathways...
- The National Center for Advancing Translational Sciences, a component of the U.S. Department of Health and Human Services' National Institutes of Health, awarded a $22,226.00 firm fixed price purchase order to MedChemExpress LLC, a New Jersey-based provider of life science research materials. The contract is to obtain 5-milligram samples of biologically active small molecules with well-defined mechanisms of action. This material will be used to create the MIPE 5.1 molecular library, a collection...